| Literature DB >> 23851568 |
Jeevan K Prasain1, Hieu D Hoang, Johnathan W Edmonds, Michael A Miller.
Abstract
Caenorhabditis elegans is emerging as a powerful animal model to study the biology of lipids(1-9). Prostaglandins are an important class of eicosanoids, which are lipid signals derived from polyunsaturated fatty acids (PUFAs)(10-14). These signalling molecules are difficult to study because of their low abundance and reactive nature. The characteristic feature of prostaglandins is a cyclopentane ring structure located within the fatty acid backbone. In mammals, prostaglandins can be formed through cyclooxygenase enzyme-dependent and -independent pathways(10,15). C. elegans synthesizes a wide array of prostaglandins independent of cyclooxygenases(6,16,17). A large class of F-series prostaglandins has been identified, but the study of eicosanoids is at an early stage with ample room for new discoveries. Here we describe a procedure for extracting and analyzing prostaglandins and other eicosanoids. Charged lipids are extracted from mass worm cultures using a liquid-liquid extraction technique and analyzed by liquid chromatography coupled to electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). The inclusion of deuterated analogs of prostaglandins, such as PGF2 α-d4 as an internal standard is recommended for quantitative analysis. Multiple reaction monitoring or MRM can be used to quantify and compare specific prostaglandin types between wild-type and mutant animals. Collision-induced decomposition or MS/MS can be used to obtain information on important structural features. Liquid chromatography mass spectrometry (LC-MS) survey scans of a selected mass range, such as m/z 315-360 can be used to evaluate global changes in prostaglandin levels. We provide examples of all three analyses. These methods will provide researchers with a toolset for discovering novel eicosanoids and delineating their metabolic pathways.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23851568 PMCID: PMC3728984 DOI: 10.3791/50447
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355
|
|
|
|
|
| 20-hydroxy PGE2 | 9.43 | 367 | 349, 331, 287, 234, 189, 129, 109 |
| PGF3- | 11.26 | 351 | 333, 307, 289, 271, 245, 219, 209, 193, 191, 171, 165, 111 |
| Thromboxane B2 | 11.66 | 369 | 289, 191, 177, 169, 151 |
| PGF2- | 11.80 | 353 | 335, 309, 291, 273, 263, 247, 235, 209, 193, 171, 165, 111 |
| PGF1- | 11.79 | 355 | 337, 319,311, 301, 293, 275, 265, 237, 211, 195 |
| Lipoxin B4 | 12.38 | 351 | 201, 191,189, 165, 155, 115, 107, 71, 59 |
| PGD2 | 12.56 | 351 | 315, 271,203, 189 |
| 5(S), 6(R)- Lipoxin A4 | 12.83 | 351 | 235, 217, 189, 144, 135, 115, 99, 59 |
| PGA2 | 14.02 | 333 | 315, 297, 271, 235, 191, 189, 175, 163, 137, 113, 109 |
| Δ12-PGJ2 | 14.20 | 333 | 271, 189, 123 |
| Leukotriene B4 | 14.73 | 335 | 181, 109, 93, 71, 69, 59, 57 |
| 15d-Δ12,14-PGJ2 | 16.80 | 315 | 297, 271, 217, 203, 158 |
| 5(S)-HpETE | 17.88 | 335 | 97, 83, 81, 57 |
|
|
|
|
|
| F1 (CePGF1) | 1 | 355 | 319, 301, 311, 293, 275, 265, 237, 223, 211, 195, 157 |
| F1 | 2 | 355 | 311, 301, 293, 275, 265, 211, 195, 167, 157 |
| F2 (CePGF2) | 3 | 353 | 309, 291, 273, 263, 247, 209, 193, 171, 165, 127 |
| F2 | 4 | 353 | 309, 291, 273, 263, 255, 247, 219, 209, 193, 171, 113 |
| F3 | 5 | 351 | 315, 307, 289, 275, 249, 205, 193, 191, 167, 153, 139 |
| F3 | 6 | 351 | 333, 289, 271, 261, 245, 223, 193, 191, 163 |